Corium International Inc (CORI) was Reiterated by Needham to “Buy” while Lowering the Price Target of the company shares to $ 10 from a previous price target of $12 . Needham advised their Clients and Investors in a research report released on Feb 14, 2017.
Several company insiders have filed Insider transactions , on May 20, 2016, Eric Bjerkholt (director) purchased 24,500 shares at $3.63 per share price. According to the SEC, on May 16, 2016, David Greenwood (director) purchased 3,000 shares at $3.58 per share price. On Feb 26, 2015, Peter D Staple (CEO) purchased 3,600 shares at $6.99 per share price, according to the Form-4 filing with the securities and exchange commission.
Corium International Inc closed down -0.02 points or -0.70% at $2.83 with 90,135 shares getting traded on Friday. Post opening the session at $2.85, the shares hit an intraday low of $2.82 and an intraday high of $2.9 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Corium International Inc. is a biopharmaceutical company. The Company is engaged in the development manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules or biologics including vaccines peptides and proteins as well as small molecules. Its Corplex and MicroCor platforms address the shortcomings of traditional transdermal drug delivery. Its marketed products include Clonidine TDS which is a treatment for hypertension; Fentanyl TDS which is a treatment for management of chronic pain and Crest Whitestrips are a series of five products for oral care. Its Twirla is designed to deliver both hormones at levels comparable to low-dose oral contraceptives. Its MicroCor hPTH(1?34) is a transdermal system designed to use its MicroCor technology to provide the delivery of parathyroid hormone.